In a study published today in the journal Proceedings of the National Academies of Science, researchers led by Ara Nazarian, PhD, a principal investigator in the Center for Advanced Orthopaedic Studies at BIDMC, investigated the musculoskeletal phenotype of the homozygous G608G BAC-transgenic progeria mouse model, developed at Dr. Collins’ lab at the National Institutes of Health, and determined the phenotypic changes of these mice after a five-arm preclinical trial of different treatment combinations with lonafarnib, pravastatin, and zoledronic acid.
- New shape-changing 4D materials hold promise for morphodynamic tissue engineering
- UM scientists achieve breakthrough in culturing corals and sea anemones cells
- New discoveries on the containment of COVID-19 finds travel bans are of limited value
- Baby mice have a skill that humans want – and this microchip might help us learn it
- Fantastic voyage: Nanobodies could help CRISPR turn genes on and off